Publication | Open Access
Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy
655
Citations
7
References
2000
Year
Dunnigan-type familial partial lipodystrophy causes progressive regional fat loss and insulin resistance after puberty, and its gene maps to chromosome 1q21–22 where LMNA—mutations of which cause Emery–Dreifuss muscular dystrophy—resides. The study aimed to test whether LMNA mutations underlie FPLD by exploiting the analogy between muscle wasting in EDMD-AD and adipocyte degeneration in FPLD. Sequencing LMNA in five Canadian FPLD probands identified a novel R482Q mutation that co‑segregated with the phenotype and was absent from 2000 controls, marking the first mutation linked to an adipose‑tissue degenerative disorder and suggesting LMNA may cause other tissue‑specific degenerative diseases.
Patients with Dunnigan-type familial partial lipodystrophy (FPLD) are born with normal fat distribution, but after puberty experience regional and progressive adipocyte degeneration, often associated with profound insulin resistance and diabetes. Recently, the FPLD gene was mapped to chromosome 1q21–22, which harbours the LMNA gene encoding nuclear lamins A and C. Mutations in LMNA were shown to underlie autosomal dominant Emery–Dreifuss muscular dystrophy (EDMD-AD), which is characterized by regional and progressive skeletal muscle wasting and cardiac effects. We hypothesized that the analogy between the regional muscle wasting in EDMD-AD and the regional adipocyte degeneration in FPLD, in addition to its chromosomal localization, made LMNA a good candidate gene for FPLD. DNA sequencing of LMNA in five Canadian FPLD probands indicated that each had a novel missense mutation, R482Q, which co-segregated with the FPLD phenotype and was absent from 2000 normal alleles (P = 1.1 × 10–13). This is the first report of a mutation underlying a degenerative disorder of adipose tissue and suggests that LMNA mutations could underlie other diseases characterized by tissue type- and anatomical site-specific cellular degeneration.
Page 1
Page 1